AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06420557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 1 session of neuro-reinforcement.
Study NCT06420557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 3 sessions of neuro-reinforcement.
Study NCT06420557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 5 sessions of neuro-reinforcement.
Study NCT06178523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate.
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
Study NCT06178523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate.
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
Study NCT06178523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
Study NCT06178523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: IUI (Group-B).
Study NCT05463744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC
Study NCT05463744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT06662461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Greater occipital nerve block
Description: Patients will be positioned in a prone position with their neck slightly flexed.~The trapezius , semispinalis, obliqus capitis muscles will be revealed on short-axis view.~A 25- or 21 gauge is used, with puncture point 1-1.5 cm away from the ultrasound probe.~Under the guidance of the ultrasound, GOB will performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine.
Study NCT06662461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Stellate ganglion block
Description: Patients are positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment the C7 level is confirmed. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus collis muscle are revealed on this short-axis view.~A 25- or 21 gauge is used and the puncture point is 1-1.5 cm away from the ultrasound probe The tip of the needle reach the surface of the longus collis muscle and the 5 o'clock position of the carotid artery. Under the guidance of the ultrasound, SGB is performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine.
Study NCT06666335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subcutaneous injections once daily for 6 months
Study NCT06666959 — intervention group
Intervention type: DRUG
Intervention: Anesthesia Agent
Description: intravenous anesthetic and inhalation anesthetic
Study NCT06668233 — intervention group
Intervention type: RADIATION
Intervention: CT
Description: CT Brain
Study NCT06668233 — intervention group
Intervention type: RADIATION
Intervention: CT scan
Description: Neuroimaging in case with delayed development , focal neurological symptoms or seziures
Study NCT06664840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDR diet assessment
Description: Participants will record their dietary intake on the MyRareDiet (MRD) app and nutrient content will be assessed to validate MRD compared to a traditional interviewer assessed 24 hour recall.
Study NCT06664840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hour recall
Description: A trained nutritionist will conduct a telephone multi-pass 24 hour diet recall on 3 randomized nonconsecutive days. The dietary intake will be analyzed using NDSR and metabolic pro and nutrient intake will be compared to the nutrient intake assessed with the MRD app.
Study NCT06667180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity TMS
Description: Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 mT and frequency of 50 Hz in theta bursts.
Study NCT06667180 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: The control group will receive the simulation of low-intensity TMS without magnetic field induction.
Study NCT06617247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention1: Cannabidiol
Description: Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
Study NCT06617247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2: Placebo
Description: In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (
Study NCT06666374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHL program
Description: This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding. The program comprised seven steps designed to guide patients through key aspects of oral health care, enabling them to progressively build their skills and confidence. These steps included personalized education on oral health, hands-on practice of proper oral hygiene techniques, self-assessment exercises, and strategies for overcoming barriers to good oral health.
Study NCT06666374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program
Description: Program primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
Study NCT06668753 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
Description: SGLT-2 inhibitors
Study NCT06450873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coriolus Versicolor Extract
Description: Dietary Supplement Given PO
Study NCT06450873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06667791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer guided sodium hyaluronate injections
Description: Patients will be treated with Computer guided sodium hyaluronate injections in superior TMJ space
Study NCT06667791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional sodiumhyaluronate injections
Description: Patients will be treated with conventional sodium hyaluronate injections in superior TMJ space
Study NCT06621940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Individuals will be placed on a high protein diet for 10 days.
Study NCT06621940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein Diet
Description: Individuals will be placed on a normal protein diet for 10 days.
Study NCT06621615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVL006 Injection
Description: CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
Study NCT06620120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm.
Study NCT06620120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without insoles
Description: At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm.
Study NCT06667882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase Injectable Product
Description: The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
Study NCT06667882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase Injectable Product
Description: The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
Study NCT05318534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL-0719
Description: Administration route: intravenous infusion and subcutaneous injection
Study NCT05318534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration route: intravenous infusion and subcutaneous injection
Study NCT06667817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks of exercise training (Exercise Group) will be prescribed via a smart phone application. Results from this group will be compared to results of the sedentary control group.
Study NCT05592847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigator Program
Description: Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
Study NCT06624306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone PNL
Description: Prone PNL
Study NCT06624306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone-flexed PNL
Description: Prone-flexed PNL
Study NCT04157114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAP4343
Description: Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Study NCT04157114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Study NCT04157114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized behavioral counseling
Description: Subjects receive manually-guided counseling 1 time per week for a 6 week duration
Study NCT04157114 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized behavioral counseling
Description: Subjects receive manually-guided counseling 1 time per week for a 6 week duration
Study NCT05590637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimavanserin
Description: Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Study NCT06152016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BE-FAST
Description: This intervention includes those randomized to the education with the BE-FAST mnemonic.
Study NCT06152016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: This intervention includes those randomized to the education with the FAST mnemonic.
Study NCT05130255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD2-SADA:177Lu-DOTA Complex
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
Study NCT05304715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezlotoxumab
Description: Single intravenous infusion of bezlotoxumab
Study NCT05304715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9% or 5% dextrose water
Description: Single intravenous infusion - Placebo arm
Study NCT05447624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of genicular nerves
Description: The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
Study NCT06159374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
Study NCT06010290 — intervention group
Intervention type: DRUG
Intervention: 18F-SMBT-1
Description: Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
Study NCT05672303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palmar grasp reflex
Description: The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
Study NCT06342895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nutritional support prescription and delivery monitoring feedback
Description: Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device
Study NCT06342895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual care
Description: Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
Study NCT05198193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Message Given
Description: Participants in this arm are not given any intervention.
Study NCT05198193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Message Given - Older Adults
Description: Participants in this arm are given a positively framed message from an older adult's point of view.
Study NCT05198193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Message Given - Older Adults
Description: Participants in this arm are given a negatively framed message from an older adult's point of view.
Study NCT05198193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Message Given - Younger Adults
Description: Participants in this arm are given a positively framed message from an adult child's point of view.
Study NCT05198193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Message Given - Younger Adults
Description: Participants in this arm are given a negatively framed message from an adult child's point of view.
Study NCT05643417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
Study NCT04733911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
Study NCT04733911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
Study NCT04733911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 300 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Description: Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
Study NCT04751461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product
Study NCT04751461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product
Study NCT05590637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Study NCT05633992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Description: Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.